KHKuan-Chu Hou

Kuan-Chu Hou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kuan-Chu Hou has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Coffee and tea consumption and dementia risk: The role of sex and vascular comorbidities

    by Kuan-Chu Hou, Yen-Ching Chen, Ta-Fu Chen, Yu Sun, Li-Li Wen, Ping-Keung Yip, Yi-Min Chu, Jeng-Min Chiou, Jen-Hau Chen


  • Open Access

    Consumption of coffee and tea and the risk of dementia – role of sex and vascular comorbidities

    by Kuan‐Chu Hou, Yen‐Ching Chen, Ta‐Fu Chen, Yu Sun, Li‐Li Wen, Ping‐Keung Yip, Yi‐Min Chu, Jeng‐Min Chiou, Jen‐Hau Chen

    Background: Coffee and tea consumption has been shown to associate with the risk of dementia. However, little is known about how sex and vascular comorbidities (type 2 diabetes, hypertension, and hypercholesterolemia) modify this association.Method: This is a multi‐center case‐control study. We recruited 278 Alzheimer’s disease (AD) and 102 small‐vessel vascular dementia (VaD) patients aged 60 or older from three teaching hospitals in Taiwan from 2007 to 2010; controls (n = 468) were recruited from the health checkup program during the same period of time. The outcomes of this study are clinically diagnosed AD and VaD. Information on coffee and tea consumption and the history of type 2 diabetes, hypertension, and hypercholesterolemia were collected based on questionnaires and medical charts. A multinomial logistic regression model was utilized to evaluate 1) the association of coffee and tea consumption with dementia risk, and 2) how sex and vascular risk factors modified these associations.Result: Different combinations and quantities of coffee and tea consumption protected against AD and VaD. Our analyses demonstrated consumption of three or more cups of coffee or tea per day was associated with a decreased risk of AD [adjusted odds ratio (aOR) = 0.42; 95% confidence interval (CI) = 0.22‐0.78)] and VaD (aOR = 0.42; 95% CI = 0.19‐0.94). After stratification, these associations became more evident in females for AD (aOR = 0.15; 95% CI = 0.05‐0.46) and in males for VaD (aOR = 0.06; 95% CI = 0.01‐0.50). Similarly, hypertensive participants consuming higher quantities of coffee and tea had a decreased risk of AD (aOR = 0.30; 95% CI = 0.11‐0.78). Moreover, hypercholesterolemia significantly modified the association of coffee or tea consumption with the risk of dementia (Pinteraction < 0.001).Conclusion: Coffee and tea consumption was associated with a decreased risk of AD and VaD. Sex and vascular comorbidities differentially modified the association of coffee and tea consumption with the risk of dementia.

  • Open Access

    Ultrasensitive and High‐Resolution Protein Spatially Decoding Framework for Tumor Extracellular Vesicles

    by Chi‐An Cheng, Kuan‐Chu Hou, Chen‐Wei Hsu, Li‐Chiao Chiang

    Proteins localized on the surface or within the lumen of tumor‐derived extracellular vesicles (EVs) play distinct roles in cancer progression. However, quantifying both populations of proteins within EVs has been hampered due to the limited sensitivity of the existing protein detection methods and inefficient EV isolation techniques. In this study, the eSimoa framework, an innovative approach enabling spatial decoding of EV protein biomarkers with unmatched sensitivity and specificity is presented. Using the luminal eSimoa pipeline, the absolute concentration of luminal RAS or KRASG12D proteins is released and measured, uncovering their prevalence in pancreatic tumor‐derived EVs. The pulldown eSimoa pipeline measured absolute protein concentrations from low‐abundance EV subpopulations. The eSimoa assays detected EVs in both PBS and plasma samples, confirming their applicability across diverse clinical sample types. Overall, the eSimoa framework offers a valuable tool to (1) detect EVs at concentrations as low as 105 EV mL−1 in plasma, (2) quantify absolute EV protein concentrations as low as fM, and (3) decode the spatial distribution of EV proteins. This study highlights the potential of eSimoa in identifying disease‐specific EV protein biomarkers in clinical samples with minimal pre‐purification, thereby driving advancements in clinical translation.